Fly-to-bedside resource offers new hope for COVID-19 treatments

Im­mutep has raised about $53 mil­lion to bankroll its LAG-3 drugs across on­col­o­gy and au­toim­mune dis­eases, giv­ing it a cash run­way to the first quar­ter

Lyell Im­munophar­ma is lay­ing off 25% of its work­force, and its chief med­ical of­fi­cer is leav­ing, ac­cord­ing to the Bay Area biotech com­pa­ny’s third-quar­ter re­port.